FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

The benefits of interferon beta-1a treatment included:

  • reduction in relapse rates:
    • 27% for the 22 mcg group
    • 33% for the 44 mcg group

  • prolongation in the time to first relapse:
    • 3 months for the 22 mcg group
    • 5 months for the 44 mcg group

  • time to sustained progression was significantly longer in both treatment groups (p<0.05)

  • disease burden as assessed by T2-weighted MRI scans was significantly lower in both treatment groups

Last reviewed 01/2018